Skip to content

Summit Therapeutics SMMT Ratios & Valuation

FY'25FY'24FY'23FY'22
Returns
Return on equity-206.1%-111pp-94.9%+507pp-601.8%-527pp-75.1%+33.8pp
Return on assets-181.9%-113pp-69.3%+72.5pp-141.8%-122pp-20.3%+61.8pp
Liquidity
Current ratio9.9×-0.3×10.2×+0.9×9.3×-7.6×16.9×+13.1×
Quick ratio9.9×-0.3×10.2×+0.9×9.3×-7.6×16.9×+13.1×
Cash ratio0.2×-0.2×0.4×-0.2×0.5×-1.1×1.6×-1.2×
Leverage
Debt-to-equity0.0×-1.3×1.4×-2.6×3.9×+3.9×
Debt-to-assets0.0×-0.5×0.5×-0.2×0.8×+0.7×
Per Share
Book value per share$0.88+62.9%$0.54+331%$0.13-80.9%$0.66+3.6%
Valuation
Market capitalization$13.02B-1.1%$13.16B+618%$1.83B-38.6%$2.98B+58.0%
Enterprise value$13.02B-1.0%$13.15B+582%$1.93B-43.7%$3.42B+88.0%
Price / book19.8×-14.1×33.9×+10.3×23.6×0.0×23.6×+0.9×
Free cash flow yield-2.5%-1.4pp-1.1%+3.1pp-4.2%
Earnings yield-8.3%-6.6pp-1.7%+31.9pp-33.6%-30.9pp-2.6%+2.1pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Summit Therapeutics's ratios come from?
Every ratio is computed from Summit Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.